On 29 October 2024, UK’s National Institute for Health and Care Excellence (NICE) recommended Pfizer’s Elrexfio® (elranatamab) for use in the NHS’ Cancer Drugs Fund. The Cancer Drugs Fund provides funding for certain cancer medicines before they have been approved by NICE for use in the NHS. Elranatamab is a sub-cutaneous injection therapy for the treatment of multiple myeloma.
In the media release, the director of medicines evaluation at NICE states that use of Elrexfio® through the Cancer Drugs Fund “will give people access to this promising new fourth-line treatment while longer-term data on its use is collected to establish whether it is clinically and cost effective”.
Elrexfio® is approved for relapsed or refractory multiple myeloma in the US (August 2023) and EU (December 2023).